Greifenberg, Ann Katrin

Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors

Zhang, T., Kwiatkowski, N., Olson, C. M., Dixon-Clarke, S. E., Abraham, B. J., Greifenberg, A. K., Ficarro, S. B., Elkins, J. M., Liang, Y., Hannett, N. M., et al. (2016) · Nature Chemical Biology

Protein Degradation and InhibitorsHeterocyclic Compound Synthesis and Bioactivity

Cited by 374

CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA Wild-Type and mutated models of Triple-Negative breast Cancer

Johnson, S. F., Cruz, C., Greifenberg, A. K., Dust, S., Stover, D. G., Chi, D., Primack, B., Cao, S., Bernhardy, A. J., Coulson, R., et al. (2016) · Cell Reports

PARP inhibition in cancer therapyAdvanced Breast Cancer Therapies

Cited by 291

Structural and functional analysis of the Cdk13/Cyclin K complex

Greifenberg, A. K., Hönig, D., Pilarova, K., Düster, R., Bartholomeeusen, K., Bösken, C. A., Anand, K., Blazek, D., & Geyer, M. (2016) · Cell Reports

Genomics and Chromatin DynamicsCancer-related Molecular Pathways

Cited by 157